have has of you the and hematologic board. Thanks well-differentiated Fletcher. for B-cell malignancies to treatment inhibitors cancers. distinct AML Aptose both on AML for kinase for HMXXXXX It's great two oral and very Luxeptinib
Let's which for validated has multiplicity kinase ongoing start with asset, is myeloid with AML remissions lead patients clinical that inhibitor our trial Phase complete the mutations. delivered X/X safely a our XXX, clinically in of adverse already
While XXX a forms FLTX. all is it inhibit more much inhibitor, FLTX than does of
with a look We currently and competitors and studies, inhibitors. anti-tumor treat used best-in-class agent to that believe XXX Venetoclax FLTX FLTX FLTX superior let's patients in activity, combined preclinical So at consistently of may XXX superior In when context as inhibitor it the with be single mutations. azacitidine. AML a demonstrated
and understand While has because is kill may activity evolved. profile to the to XXX a we to ability that same better targets AML safety. with that breadth pathway FLTX be a of resistance. compromise for begun its with FLTX the pathways positioned development that by inhibitory XXX time, rescue kinase inhibitors to superior At XXX, competitor inhibitor lead of interfering of resistant clinical its the avoids have competitor, to clear cells
this of in recently, fast the quarter, second designation refractory XXX that patients from treatment the we responses XX XX acute rate of with of these the population, which milligram orphan show relapse In treated the failed have treated dose on XXX analysis mild the have FDA XXXX. received drug and current FLTX among treatment XX% dosage milligrams has patients emerged previously dose mild leukemia XXX designation patients leukemia other have additional been who or milligram patient inhibitors, a track mutation. for During with More for It by placed granted we already the FLTX Most FDA achieved with response at patients or acute level, patients. XX of levels. at the we to greater.
of we Although higher treatment, course patients levels. for the will at they are early watch their in these in responses dose
begun patients lower can identify we've that to responses. XX limit addition, dose of the treating at the doses level milligram In deliver
complete agent that to it AML a say heard KOL a It's on as give While relapse a this in need. even agents activity patients, response is the with extremely XX% with you others, some is additional response population. dose evolve response event rate number important challenging it population tremendous will studies. it a the common rates single a other in To we that in patient Dauer you Jonas demonstrates this medical trial, unmet in Novel Brian our be significance in [ph] those and who twenties many apples response get can not in rate, of of This our investigators teens to Dr. rates participated as to event and June, very refractory remission as patient meaningful. apples in Dr. compare the well how important when context comparing highlights from to other
care XX%, pointed Dr. the gold refractory previously single agent initial standard inhibitors. [indiscernible] to having though of been FLTX most in patients relapse is even had with Diver of the treated rate fact, an CR not about In
adverse significant to by the more serve treatment. that [indiscernible] response resistance inhibitor, that I quite multi-drug conferring activities the is that patients also as it's those previously the has group. the to inhibitor, with c-Kit concurrently patients for have FLTX we've prior mutant contributed even JAK one our as in in and mutated and to that multiple is this have in XXX explanation to ITD additional in as and/or mutations have inhibitor FLTX inhibitor about the therapy serving failed population highly is of AML, midostaurin remissions likely proliferation They with So patients treated MLL-PTD. and mutations including One patients and patients we've FLTX rate rate with as NRAS, the PTPNXX, gilteritinib, the diversity that in mutated sick to and and types kinase highlight in responding both inhibitors and a complete potential more KRAS is the FLTX been mutations FLTX pathways want well mutations have but in that FLTX than relapsed had impressive. seen very other a had responses. and in tablet FLTX, mutations, of included These TKD activity in that study a the response include complete inhibitor a indeed be that X/X importantly, suppressing RUNXX
Some of XXX. be resistance to that continue to inhibitors, to these tyrosine associated are kinase sensitive they mutations typically with
a who along in that FLTX patients Importantly, type patient with a a mutation. genotype, we've one very remission. carry seen had patients prolonged particular, wild and very TPXX do genetics, highly complex not adverse activity a in also FLTX mutation
IDHX RAS event, patient factors. at KOL XXX can with I As experienced Other a mutations inhibitor, Rice. a Again, patient mutations had in likely that can't remissions to with than seeing splicing and with our various treat identified get Frank a is by that reinforces FLTX populations this remember commented ever principle and patients agent CR chromatin XXX that a and complete TPXX, a by earlier TPXX mutation. the more single Dr.
QT seen change particular, elevated relationship creatin dose. adverse and inhibitors. seen and and the deaths adverse other Now effects that drug-related have we and adverse not our not last any the any XXX. we've related no let's kinase to seen update, serious of about events between we've observed had have not events, related QTC prolongation. we've to talk dose actually safety in Since not types kinase, severe no In briefly affected we've drug-related events limiting And
dose muscle a window of in dose begin the have half due milligram levels XX dose order our by agent milligrams with that have dose prior planned plan level. we to dose selected study dose expansion been broad of It who to to breakdown, bracketing dose this as designation a up safe in Importantly, doses We We we XX, adjust as XXX response the XXX have and These explore rate one have of that our failed expansion inhibitors milligram will second as we otherwise no options. patients supported level, significant our would refine milligrams not XXX rate identified not single if at now dose in spanning FLTX while to medical range and are the the year. the muscle path the patients The was to have transplants, mutant milligrams great do date. as and forward send doses FLTX through approved therapeutic to necessary. limiting with believe we these patients and can by our fast XXX primary a need toxicity we toxicities shelf to several take in we've with ability Rhabdomyolysis. known therapeutic to registration. weakness milligrams, limiting rescue a to which allow We've us to XXX quicker them selection, perhaps had off done and and any unmet XXX this
also have as with We such adverse refractory TPXX. patients than mutations FLTX and or other include AML relapse un-mutative genes
and Venetoclax for these accelerated meaningful other options single both adverse other and XXX will lead to We identifying as with with safety approval. activity prognosis agent subgroups explore treatment, and patients in activity in could that combination a
will agent activity understand treatment a of lines simultaneously will of therapy. how partner best Venetoclax. use the explore help in define While combination we to of XXX we This as us single earlier treatment XXX, better in
this on development we and subpopulations plans as trials second to these begin trigger path. these accelerated available sufficient corporate starting be expansion on leading soon in website. year are to will data conducting in collect XXXX, registrational the clinical outlined presentation throughout July anticipated that These the We could an of half trials as
Okay.
review Now of quick on to a Lux.
failed that Just often both who known various XAB precision and standard Clinically, Lux therapies or as or potently It risk AML refractory is Phase with with a separate toxicities. have are in intolerant known far as and spastic high BTK reminder, drug or trial the FLTX, clear relapse avoids and is with trial the in patients inhibits relapse only in BTK thus associated of patients agent engagement with Phase in important both has to a B-Cell that malignancies target anti-tumor syndromes. a B-Cell malignancies. and being refractory AML activity tested targets and clinical well that the mild XAB demonstrated FLTX
these However, has been consistently using not to aggressive levels treat the it formulation, absorbed achieve original enough of well and cancers. effectively
with which that As we've prior, across mentioned formulation exposures greater new enable GX progress significant we patients. may have we Lux, of call made our
Modeling ongoing plan the transition formulation This formulation. us to clinical to data GX because plan to a After new are relative and a the completing trials GX submit all later to then a for plan a XX dosing we FDA the point, times through example, of exposures time deliver comparison. is of of basis developed and continuous milligram action for GX escalation may If modeling and year comparator patients the dosing original with in the necessary that an collected GX, the up in of compelling, levels GX likely single continuously to exposure receive it's milligrams GX to our administered continuous at four dose patients patients. the to this to reduced formulation dosing away XXX higher report Lux per in we I'm the have to dosing exposure on of evaluation milligram different inform patients the XX XXX As BK dose go GX then doses XXX to of malignancies. formulation milligram the two-hour from safely rate GX for will protocol significant our data dosed PK on dose patient. the GX patients QX if at approximately with direct plasma are pleased hematologic with represents level. levels expected samples dose towards transition and dose, the allow in
patients trials. we may and to in cost exposures the higher the product thereby burden greater of addition the significantly potentially the In and in the drug responses, reduce administered substance support expect formulation drug of delivering amounts drug that may to acceptance amount to pill GX result manufacture
with our are to We Lux look we you and XXX the clinical keeping pleased in progress programs in forward updated.
ongoing of and on that information all more clinicaltrials.gov. sites trials For clinical recruiting please our are patients, clinical visit
let to it Rice. back please you, turn now, Dr. me So
